Artiva Biotherapeutics In... (ARTV)

NASDAQ: ARTV · Real-Time Price · USD

2.43

0.06 (2.53%)

At close: May 02, 2025, 3:59 PM

2.49

2.41%

After-hours: May 02, 2025, 05:36 PM EDT

2.53% (1D)

Bid	2.45
Market Cap	59.2M
Revenue (ttm)	251K
Net Income (ttm)	-55.19M
EPS (ttm)	-5.81
PE Ratio (ttm)	-0.42
Forward PE	-0.89
Analyst	Buy

Ask	2.46
Volume	208,773
Avg. Volume (20D)	301,541
Open	2.35
Previous Close	2.37
Day's Range	2.29 - 2.56
52-Week Range	1.78 - 17.31
Beta	5.29

About ARTV

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vascu...

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees 89

Stock Exchange NASDAQ

Ticker Symbol ARTV

Website https://www.artivabio.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ARTV stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 723.05% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

-10.48%

Artiva Biotherapeutics shares are trading lower af... Unlock content with Pro Subscription

News

8 months ago · fool.com

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment

Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.

8 months ago · benzinga.com

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.

9 months ago · 247wallst.com

Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares

24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.

9 months ago · seekingalpha.com

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in th...